Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00444951
Status:
COMPLETED
Last Update Posted:
2015-07-14
First Post:
2007-03-07
Brief Title:
Immunogenicity and Safety of Menactra Vaccine in Adolescents in Saudi Arabia
Sponsor:
Sanofi Pasteur a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
Evaluation of the Response to a Single Dose of Menactra in Adolescents Aged 16 to 19 Years Who Previously Received One Dose of Quadrivalent A C Y W 135 and at Least One Dose of Bivalent A C Meningococcal Polysaccharide Vaccine in Saudi Arabia
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will be conducted among adolescents in Saudi Arabia who previously received one dose of A C Y W 135 and at least one dose of A C meningococcal polysaccharide vaccine This study will evaluate the booster administration of Menactra Meningococcal A C Y and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine compared with Mencevax Meningococcal A C Y and W 135 Polysaccharide vaccinein terms of their serum bactericidal antibody responses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None